Antibody Drug Conjugates Market - By Product Type (Adcetris, Perjeta, Kadcyla), Technology (Cleavable Linker, Non-cleavable, Linkerless) Application (Blood Cancer, Breast Cancer), Target Type (CD30 Antibodies, HER2 Antibodies) & Global Forecast 2024 - 2032

Antibody Drug Conjugates Market - By Product Type (Adcetris, Perjeta, Kadcyla), Technology (Cleavable Linker, Non-cleavable, Linkerless) Application (Blood Cancer, Breast Cancer), Target Type (CD30 Antibodies, HER2 Antibodies) & Global Forecast 2024 - 2032

Antibody Drug Conjugates Market Size

Antibody Drug Conjugates Market size accounted for USD 7.7 billion in 2023 and is estimated to grow at CAGR of 14.8% to reach USD 26.6 billion by 2032. Increasing incidence of cancer globally coupled with growing demand for targeted therapies is expected to boost the market value.
 

The GLOBOCAN study carried out by the International Agency for Research on Cancer stated that in 2020, an expected of 19.3 million new cases of cancer and around 10.0 million deaths due to cancer were reported across the world. Also, antibody drug conjugates (ADCs) provide targeted delivery mechanism that allows specific recognition and binding to cancer cells, resulting in enhanced efficacy and reduced systemic toxicity compared to traditional chemotherapy.
 

Antibody drug conjugates (ADCs) are a class of targeted therapeutics designed to selectively deliver potent cytotoxic drugs to cancer cells. They are composed of three main components that include a monoclonal antibody, cytotoxic payload and a linker molecule. ADCs deliver the cytotoxic payload directly to the cancer cells while minimizing damage to healthy cells, thereby improving efficacy and reducing systemic toxicity associated with traditional chemotherapy. The specific targeting and payload delivery mechanisms of ADCs make them a promising approach in the field of cancer treatment.
 

COVID-19 Impact

Emergence of COVID-19 have impacted millions of individuals across the globe. Severity and mortality risk associated with the infection have stimulated research and development activities during the pandemic. The U.S. FDA as well as some other countries have granted emergency use authorization to few antibodies including monoclonal antibody and antibody drug conjugate for its application in COVID-19 patients with mild-to-moderate infection. For instance, Eli Lilly and Co., has received emergency use authorization for its antibody combination drug in India for the treatment of mild to moderate COVID-19 infection. Further, the U.S. FDA granted emergency use authorization to the antibody treatment developed by the GlaxoSmithKline.
 

Antibody Drug Conjugates Market Trends

Increasing prevalence of cancer worldwide have significantly created the demand for effective and targeted treatment options. Antibody drug conjugate offers unique approach by combining the specificity of monoclonal antibodies with the potency of cytotoxic drugs, intended to target and kill tumor cells while minimizing damage to healthy cells. Also, ADCs possess the potential to overcome drug resistance mechanisms observed in cancer cells, thereby increasing the effectiveness of treatment. Furthermore, antibody drug conjugate can be utilized in combination therapies and personalized medicine that allows patient specific treatment that aids to attain improved patient outcomes and enhance the patient quality of life.
 

Antibody Drug Conjugates Market Analysis

By product type, the antibody drug conjugates market is classified into Adcetris, Perjeta, Kadcyla and other product type. Kadcyla segment accounted for 32.5% of the market share in 2022. Kadcyla specifically targets cancer cells that overexpress the HER2 protein, delivering a potent chemotherapy agent directly to the tumor site. This targeted approach increases treatment efficacy while minimizing harm to healthy cells, resulting in improved patient outcomes and reduced side effects compared to traditional chemotherapy. Therefore, owing to such benefits, the drug has shown significant success in treating HER2-positive breast cancer and has been approved for use in several countries.
 

Based on technology, the antibody drug conjugates market is segmented into cleavable linker, non-cleavable linker and linkerless. The cleavable linker is expected to register over USD 14.3 billion by 2032. Cleavable linker technology is one of the significant advancements in antibody drug conjugates that enables to release the cytotoxic payload specifically within cancer cells, thereby enhancing treatment efficacy. Cleavable linker technology allows for precise delivery of potent drugs to the target site, ensuring that the cytotoxic payload is released in a controlled manner, thereby maximizing its impact on cancer cells while sparing healthy tissues.
 

By application, the antibody drug conjugates market is segmented into blood cancer, breast cancer, ovary cancer, lung cancer and other applications. The breast cancer segment is expected to grow at 15.3% by 2032. ADCs offer a targeted approach by utilizing monoclonal antibodies to specifically recognize and bind to cancer cells expressing certain proteins, such as HER2. This targeted binding enables the delivery of potent cytotoxic drugs directly to the cancer cells, resulting in enhanced efficacy and reduced toxicity. The use of ADCs in breast cancer treatment has shown promising results, including improved response rates, prolonged progression-free survival and better overall patient outcomes.
 

The target type in antibody drug conjugates market is divided into HER2 antibodies, CD30 antibodies, HER2 Antibodies and other target type. HER2 antibodies accounted for USD 3.3 billion market revenue in 2022. HER2-positive cancers, including breast and gastric cancers are characterized by overexpression of the HER2 protein. ADCs designed to target HER2 antibodies allow for precise binding and delivery of potent cytotoxic drugs to cancer cells that overexpress HER2. They serve as a crucial component in ADCs, facilitating selective targeting and payload delivery making them a valuable tool in the development of targeted cancer therapies. Furthermore, various ongoing clinical trials of ADC for breast cancer and other solid tumors is expected to increase the potential of ADCs to provide more promising treatment.
 

North America antibody drug conjugates market accounted for over 49.5% business share in 2022. The increasing prevalence of cancer and growing demand for targeted therapies is expected to boost the market gains in the North America region. Also, advanced healthcare infrastructure, presence of key players and strong R&D facilities have contributed to the significant adoption and commercial success of ADCs, thereby augmenting the market progression in the North America region.
 

Antibody Drug Conjugates Market Share

Major market players operating in the antibody drug conjugates market include

• Seagen Inc.
• Pfizer Inc.
• F.Hoffmann-La Roche Ltd
• GlaxoSmithKline plc

 These industry players majorly adopt various strategies including collaborations, acquisitions, mergers, and partnerships to create a global footprint and sustain market competition.
 

Antibody Drug Conjugates Industry News

• In April 2023, Innate Pharma have signed agreement with Takeda Pharmaceutical Company Ltd to enable research and development of antibody drug conjugates (ADCs), primarily focusing on coeliac disease. This strategy is expected to help Takeda secure exclusive rights globally to use a set of selected Innate antibodies to create, manufacture and commercialize the ADCs.
   
• In March 2023, Pfizer Inc and Seagen Inc have entered into a definitive merger agreement under which Pfizer will acquire Seagen. This acquisition is aimed at pioneering expertise in antibody-drug conjugates (ADCs) that strongly complement Pfizer’s Oncology portfolio. This acquisition is expected to help the company to gain strong foothold in antibody-drug conjugates (ADCs) market and drive revenue growth.
   

The antibody drug conjugates market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments

Click here to Buy Section of this Report

By Product Type

• Adcetris
• Perjeta
• Kadcyla
• Other product type

Technology

• Cleavable Linker
• Non-cleavable Linker
• Linkerless

Application

• Blood Cancer
• Breast Cancer
• Ovary Cancer
• Lung Cancer
• Other applications

Target Type

• CD30 Antibodies
• HER2 Antibodies
• Other target types

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA